Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1977 Jun;52(6):473–481. doi: 10.1136/adc.52.6.473

Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

J A Kanis, R G Henderson, G Heynen, J G Ledingham, R G Russell, R Smith, R J Walton
PMCID: PMC1544715  PMID: 879833

Abstract

The effects of small oral doses (1-2 microgram/day) of 1alpha-hydroxycholecalciferol, given for 1 to 2 years, have been examined in four nondialysed adolescents with chronic renal failure and bone disease. Treatment increased calcium retention and plasma calcium, and decreased plasma levels of alkaline phosphatase, hydroxyproline, and immunoreactive parathyroid hormone. X-ray abnormalities of bone regressed, and 2 patients underwent successful surgical correction of knock-knees; bone histology in these 2 was normal at the time of operation. 2 patients developed hypercalcaemia which promptly reversed when 1alpha-hydroxycholecalciferol was withdrawn. In one patient treatment was initially successful, but later there was biochemical, radiographic, and histological evidence of relapse. Long-term treatment of such patients with 1alpha-hydroxycholecalciferol may be effective and facilitate the surgical correction of deformities, but this is not invariable. Toxic effects are similar to those of vitamin D itself, but are more readily reversible.

Full text

PDF
479

Images in this article

477Fig. 6
on p.477
478Fig. 8
on p.478

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berson S. A., Yalow R. S., Aurbach G. D., Potts J. T. IMMUNOASSAY OF BOVINE AND HUMAN PARATHYROID HORMONE. Proc Natl Acad Sci U S A. 1963 May;49(5):613–617. doi: 10.1073/pnas.49.5.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berson S. A., Yalow R. S. Clinical applications of radioimmunoassay of plasma parathyroid hormone. Am J Med. 1971 May;50(5):623–629. doi: 10.1016/0002-9343(71)90117-3. [DOI] [PubMed] [Google Scholar]
  3. Catto G. R., MacLeod M., Pelc B., Kodicek E. I alpha-hydroxycholecalciferol: a treatment of renal bone disease. Br Med J. 1975 Jan 4;1(5948):12–14. doi: 10.1136/bmj.1.5948.12-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chalmers T. M., Hunter J. O., Davie M. W., Szaz K. F., Pelc B., Kodicek E. 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet. 1973 Sep 29;2(7831):696–699. doi: 10.1016/s0140-6736(73)92536-1. [DOI] [PubMed] [Google Scholar]
  5. Chertow B. S., Baylink D. J., Wergedal J. E., Su M. H., Norman A. W. Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest. 1975 Sep;56(3):668–678. doi: 10.1172/JCI108137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DENT C. E., HARPER C. M., PHILPOT G. R. The treatment of renal-glomerular osteodystrophy. Q J Med. 1961 Jan;30:1–31. [PubMed] [Google Scholar]
  7. Davie M. W., Chalmers T. M., Hunter J. O., Pelc B., Kodicek E. 1-alphahydroxycholecalciferol in chronic renal failure. Studies of the effect or oral doses. Ann Intern Med. 1976 Mar;84(3):281–285. doi: 10.7326/0003-4819-84-3-281. [DOI] [PubMed] [Google Scholar]
  8. Fournier A. E., Bordier P. J., Gueris J., Chanard J., Marie P., Ferriere C., Osario M., Bedrossian J., de Luca H. F. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease. Proc Eur Dial Transplant Assoc. 1976;12:227–236. [PubMed] [Google Scholar]
  9. Henderson R. G., Kanis J. A., Ledingham J. G., Oliver D. O., Russel R. G., Smith R., Walton R. J. Comparative effect of 1alpha-hydroxycholecalciferol in children and adults with renal glomerular osteodystrophy. Calcif Tissue Res. 1976 Aug;21 (Suppl):221–225. [PubMed] [Google Scholar]
  10. Henderson R. G., Russell R. G., Ledingham J. G., Smith R., Oliver D. O., Walton R. J., Small D. G., Preston C., Warner G. T. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet. 1974 Mar 9;1(7854):379–384. doi: 10.1016/s0140-6736(74)93149-3. [DOI] [PubMed] [Google Scholar]
  11. Holick M. F., DeLuca H. F. Vitamin D metabolism. Annu Rev Med. 1974;25:349–367. doi: 10.1146/annurev.me.25.020174.002025. [DOI] [PubMed] [Google Scholar]
  12. Mason J. B., Hay R. W., Leresche J., Peel S., Darley S. The story of vitamin D: from vitamin to hormone. Lancet. 1974 Mar 2;1(7853):325–329. [PubMed] [Google Scholar]
  13. Naik R. B., Gosling P., Price C. P., Robinson B. H., Dabek J. T., Heath D. A., James H. M., Kanis J. A., Smith R. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol. Br Med J. 1976 Jul 10;2(6027):79–83. doi: 10.1136/bmj.2.6027.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peacock M., Gallagher J. C., Nordin B. E. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man. Lancet. 1974 Mar 9;1(7854):385–389. doi: 10.1016/s0140-6736(74)93150-x. [DOI] [PubMed] [Google Scholar]
  15. Pendras J. P. Parathyroid disease in long-term maintenance hemodialysis. Arch Intern Med. 1969 Sep;124(3):312–321. [PubMed] [Google Scholar]
  16. Pierides A. M., Ellis H. A., Simpson W., Dewar J. H., Ward M. K., Kerr D. N. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy. Lancet. 1976 May 22;1(7969):1092–1095. doi: 10.1016/s0140-6736(76)90061-1. [DOI] [PubMed] [Google Scholar]
  17. Reiss E., Canterbury J. M. Blood levels of parathyroid hormone in disorders of calcium metabolism. Annu Rev Med. 1973;24:217–232. doi: 10.1146/annurev.me.24.020173.001245. [DOI] [PubMed] [Google Scholar]
  18. STANBURY S. W., LUMB G. A. Metabolic studies of renal osteodystrophy. I. Calcium, phosphorus and nitrogen metabolism in rickets, osteomalacia and hyperparathyroidism complicating chronic uremia and in the osteomalacia of the adult Fanconi syndrome. Medicine (Baltimore) 1962 Feb;41:1–34. [PubMed] [Google Scholar]
  19. Smith R., Russell R. G., Bishop M. C., Woods C. G., Bishop M. Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. Q J Med. 1973 Apr;42(166):235–256. [PubMed] [Google Scholar]
  20. Stanbury S. W. The treatment of renal osteodystrophy. Ann Intern Med. 1966 Nov;65(5):1133–1138. doi: 10.7326/0003-4819-65-5-1133. [DOI] [PubMed] [Google Scholar]
  21. Tougaard L., Sorensen E., Brochner-Mortensen J., Christensen M. S., Rodbro P., Sorensen A. W. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet. 1976 May 15;1(7968):1044–1047. doi: 10.1016/s0140-6736(76)92220-0. [DOI] [PubMed] [Google Scholar]
  22. Walton R. J., Bijvoet O. L. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975 Aug 16;2(7929):309–310. doi: 10.1016/s0140-6736(75)92736-1. [DOI] [PubMed] [Google Scholar]
  23. Zerwekh J. E., Brumbaugh P. F., Haussler D. H., Cork D. J., Haussler M. R. 1Alpha-hydroxyvitamin D3. An analog of vitamin D which apparently acts by metabolism to 1alpha, 25-dihydroxyvitamin D3. Biochemistry. 1974 Sep 24;13(20):4097–4102. doi: 10.1021/bi00717a006. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES